Over the past few years, substantial advances have been made in understanding the
pathogenesis, evolution, and complexity of mast cell neoplasms. New diagnostic and …

The origin and functions of mast cells (MCs) have been debated since their description by
Paul Ehrlich in 1879. MCs have long been considered'reactive bystanders' and'amplifiers' in …

Abstract In BCR-ABL1+ leukemia, drug resistance is often associated with up-regulation of
BCR-ABL1 or multidrug transporters as well as BCR-ABL1 mutations. Here we show that the …

Acute myeloid leukemia (AML) is a life-threatening stem cell disease characterized by
uncontrolled proliferation and accumulation of myeloblasts. Using an advanced RNAi …

Mastocytosis is a myeloid neoplasm characterized by abnormal accumulation and frequent
activation of mast cells (MCs) in various organs. Organ systems typically involved are the …

Stat5 is constitutively activated in many human cancers affecting the expression of cell
proliferation and cell survival controlling genes. These oncogenic functions of Stat5 have …

Systemic mastocytosis (SM) is a heterogeneous disease, vast majority of these patients
have a gain of function mutation in the gene encoding the tyrosine kinase KIT (KITD816V). A …

Systemic mastocytosis either presents as aggressive neoplasm with short survival time or
indolent systemic mastocytosis with normal life expectancy. In both instances, neoplastic …

Mast cells are tissue resident, innate immune cells with heterogenous phenotypes tuned by
cytokines and other microenvironmental stimuli. Playing a protective role in parasitic …

Systemic mastocytosis is a heterogeneous disease characterized by the accumulation of
neoplastic mast cells in the bone marrow and other organ organs/tissues. Mutations in KIT …